Microbot Medical Inc. (MBOT) Stock Score, Valuation & Financial Research

Microbot Medical Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MBOT

Microbot Medical Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.07. These figures are a research snapshot, not a buy or sell recommendation.

What Microbot Medical Inc. does

Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Microbot Medical is a commercial-stage medical device company that develops robotic endoluminal surgery systems. The company generates revenue through the commercialization and sale of its proprietary robotic platforms, such as the LIBERTY system, targeting the minimally invasive surgery market.

Products and services

  • The company's primary product is the LIBERTY Endovascular Robotic System, a single-use, remotely operated robotic platform designed for peripheral endovascular procedures.

Brands and product families

  • LIBERTY — The company's flagship single-use, remotely operated robotic system for peripheral endovascular procedures. Source

Customer types

Hospitals and Ambulatory Surgery Centers.

Suppliers, materials and equipment

  • Contract Manufacturers — The company relies on third-party contract manufacturers for the production and assembly of its medical device components. Source

Competitors and product-market comparisons

  • Intuitive Surgical, Inc. — A developer of robotic-assisted surgical systems that competes in the broader robotic surgery market. Source
  • Johnson & Johnson (Auris Health) — A major medical device company with robotic surgery platforms for endoluminal procedures. Source

Business strengths to evaluate

  • FDA 510(k) clearance for the LIBERTY system Source
  • Proprietary single-use robotic technology Source

Business risks and research considerations

  • History of operating losses and lack of significant revenue Source
  • Dependence on third-party manufacturers and suppliers Source

Sources: Company research source · LIBERTY · FDA 510(k) clearance for the LIBERTY system · History of operating losses and lack of significant revenue

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MBOT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.07
Market capitalization:
48.76M (currency not supplied)
Revenue:
USD 346K
Net income:
USD -16.34M
Free cash flow:
USD -13.11M
Cash:
USD 3.15M
Total debt:
USD 876K
EPS:
USD -0.26

What stands out

  • Free cash flow is USD -13.11M, negative for the stored period.
  • The balance sheet shows USD 3.15M of cash versus USD 876K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -3787.9% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -4722.3% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 2.28M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MBOT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MBOT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MBOT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MBOT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MBOT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MBOT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.